KEI Staff's blog | Knowledge Ecology International

Interview with David Hammerstein regarding negotiations on WIPO treaty for persons who are blind or have other disabilities

Posted on March 7, 2011 by KEI Staff

David Hammerstein is a former Member of the European Parliament from Spain. He now works for the Trans-Atlantic Consumer Dialogue (TACD). Among other things, he is an advocate for a new WIPO copyright treaty for persons who are blind or have other disabilities. The following is an interview with David, carried out from March 3 to March 6 by email.

Continue Reading →

Nine civil society groups write WHO Executive Board about conflict of interest on WHO R&D Financing group

Posted on January 20, 2011 by KEI Staff

On January 20, 2011, 9 civil society organizations sent a letter to the WHO Executive Board registering an objection to the selection of Dr. Paul Herrling of Novartis to the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination. The groups signing the letter were:

CIDEPRO
Déclaration de Berne – Berne Declaration
HAI Europe
HAI Global
Health GAP (Global Access Project)

Continue Reading →

WHO Conflict of Interest Guidelines

Posted on January 20, 2011 by KEI Staff

WHO has kindly made available its conflict of interest guidelines. Apparently they are not available from the public web page. Attached are two documents:

A few of the many interesting provisions follow:

I. MEANING OF “CONFLICT OF INTEREST”

Continue Reading →

Uncategorized

U.S. Department of State cables regarding Brazil and pharmaceutical patents and prices – 1986-1987

Posted on August 12, 2010 by KEI Staff

Background

Beginning in 1985, the United States government (USG) diplomatic and trade officials have engaged in wide ranging activities aimed at changing global norms for the protection of intellectual property rights, with a particular emphasis on the IPR protections for pharmaceutical products.

This note reports on U.S. Department of State cables sent in 1986 and 1987, that discussed the U.S. government efforts to change policies in Brazil on the intellectual property protection for pharmaceutical products. The cables have been obtained by KEI with a FOIA request.

Continue Reading →

Letter to President of Mexico regarding ACTA

Posted on August 11, 2010 by KEI Staff

The following is an August 10, 2010 letter written by Alberto Cerda Silva, a Research Associate of Knowledge Ecology International, to Felipe Calderón Hinojosa, Presidente Constitucional de los Estados Unidos Mexicanos, regarding the position of the Mexican government in the ACTA negotiations.

Continue Reading →

Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs)

Posted on August 7, 2010 by KEI Staff

(Cite as Molly Redfield Ward, Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs), KEI Research Note 2010:3) A PDF version of this document is available here. Notes on the 2004… Continue Reading →

April 28 TACD meeting on ACTA and Consumers, at the US Department of Commerce in Washington, DC

Posted on April 11, 2010 by KEI Staff

See updates on TACD web page here:

On April 28, TACD will be holding a meeting from 9 am to 3 pm at the U.S. Department of Commerce, in Washington, DC, to discuss the proposed Anti-Counterfeiting Trade Agreement (ACTA).

Continue Reading →

PhRMA’s asks regarding special 301, drug pricing and reimbursement

Posted on March 18, 2010 by KEI Staff

Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as ‘Market Access Barriers.’ In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.

CHINA

Continue Reading →

Jeffrey Kindler rewarded by Pfizer for his influence with governments

Posted on March 10, 2010 by KEI Staff

On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.

Continue Reading →

Billy Tauzin’s 2008 compensation from PhRMA was $4,476,157

Posted on February 13, 2010 by KEI Staff

Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.

PhRMA’s 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:

Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465

Total: $4,476,157
Continue Reading →

Author: KEI Staff

Interview with David Hammerstein regarding negotiations on WIPO treaty for persons who are blind or have other disabilities

Nine civil society groups write WHO Executive Board about conflict of interest on WHO R&D Financing group

WHO Conflict of Interest Guidelines

U.S. Department of State cables regarding Brazil and pharmaceutical patents and prices – 1986-1987

Background

Letter to President of Mexico regarding ACTA

Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs)

April 28 TACD meeting on ACTA and Consumers, at the US Department of Commerce in Washington, DC

PhRMA’s asks regarding special 301, drug pricing and reimbursement

Jeffrey Kindler rewarded by Pfizer for his influence with governments

Billy Tauzin’s 2008 compensation from PhRMA was $4,476,157

Categories